Evidence map›Paper›PMID 42743545›Full record

ReviewJMIR cancer2026

AI Agents for Multimodal Oncology Diagnosis: Toward Transparent and Traceable Clinical Decision Support.

Liuyang Yang, Liyu Shan, Xiangmei Yao, Renbin Zhao, Zengzheng Li, Shuai Feng, Yajie Wang

Abstract readReview
In one paragraph

Review in JMIR cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Liuyang Yang *Department of Hematology, The First People's Hospital of Yunnan Province, Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, China.ORCID 0000-0001-6140-6846
Liyu Shan *The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Kunming, Yunnan, China.ORCID 0000-0002-6700-1425
Xiangmei Yao *Department of Hematology, The First People's Hospital of Yunnan Province, Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, China.ORCID 0000-0002-0093-1396
Renbin ZhaoDepartment of Hematology, The First People's Hospital of Yunnan Province, Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, China.ORCID 0009-0009-7234-8675
Zengzheng LiDepartment of Hematology, The First People's Hospital of Yunnan Province, Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, China.ORCID 0000-0003-3333-6267
Shuai FengDepartment of Hematology, The First People's Hospital of Yunnan Province, Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, China.ORCID 0000-0001-6889-4993
Yajie WangDepartment of Hematology, The First People's Hospital of Yunnan Province, Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, China.ORCID 0009-0008-5981-5761

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer diagnosis depends on data from radiology, digital pathology, molecular profiling, laboratory testing, and longitudinal clinical records. AI performs well in selected tasks, but most systems remain narrow and disconnected from the iterative reasoning required in oncology. This Viewpoint defines an AI agent as a feedback-driven system that maintains task state, selects among governed tools, observes results, and revises its plan under explicit safety constraints. This definition separates agents from multimodal foundation models, retrieval-augmented generation, and fixed workflow automation. We organize the discussion across multimodal data collection, preprocessing, fusion and representation learning, and diagnostic decision support. We distinguished agent-level evidence, component- or infrastructure-level evidence, and prospective propositions throughout. Clinical translation will require resilient failure handling, guideline version control, prospective evaluation, computational and workflow feasibility, and clinician authority over final decisions. The near-term opportunity is therefore transparent and traceable clinical decision support rather than autonomous cancer diagnosis.

Indexed as

Artificial IntelligenceDecision Support Systems, ClinicalMedical OncologyNeoplasmsHumansartificial intelligence agentclinical decision supportdiagnostic workflowhuman–artificial intelligence collaborationlarge language modelmultimodal oncology diagnosis

Identifiers

PMID42743545
PMCPMC13624588

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.